Symbicort is a prescription drug used to treat asthma and chronic obstructive pulmonary disease (COPD). Learn how to lower long-term costs and more.

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...

Viatris announced the launch of Breyna ™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca’s Symbicort ®.. Breyna is a metered-dose ...

The first Symbicort generic, simply referred to as budesonide/formoterol inhaler, was approved by the Food and Drug Administration (FDA) in February 2020 and is roughly half the cost of Symbicort.

Keep reading to learn about the common, mild, and serious side effects that Symbicort can cause. For a general overview of the drug, including details about its uses, see this article.

This extended the lapse date of a key patent for Symbicort to July 2023. But with just six months until that patent expires, Viatris could soon launch its generic version of Symbicort, known as ...

An AstraZeneca report said Symbicort sales earned the company more than $2.7 billion last year. The U.S. Food and Drug Administration tentatively approved Viatris' Breyna, the first generic ...

Viatris and Kindeva declared victory over a fourth patent on AZ’s drug-device combo Symbicort, which brought home more than $2.7 billion in sales for the British pharma last year.

Last December, Viatris(NASDAQ: VTRS) and Kindeva Drug Delivery lost in court against AstraZeneca(NASDAQ: AZN) over a patent dispute regarding one of the latter's patents for its asthma and chronic ...